Price
Financials
Consolidated, Rs crore| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS in Rs | 128.13 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Expenses | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 443 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 34% |
| Other Income | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 29 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS in Rs | 128.02 | 236.60 | 356.04 | 442.27 | 945.21 | 14.27 | 15.31 | 16.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 24% | 14% | 24% | ||
| Compounded Profit Growth | % | 39% | 40% | 20% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 32% | 32% | 25% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 |
| Other Liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Fixed Assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash from Investing Activity | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Cash from Financing Activity | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | -0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/OP | 62% | 104% | 22% | 78% | 60% | 47% | 56% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | 36% | 36% | 33% | 49% | 36% | 28% |
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters | 76.16% | 76.16% | 76.16% |
| FIIs | 1.67% | 1.55% | 1.81% |
| DIIs | 17.59% | 18.11% | 15.64% |
| Public | 4.57% | 4.18% | 6.39% |
| No. of Shareholders | 43,599 | 36,503 | 35,695 |
Fundamentals
Market Cap₹ 13,500 Cr.
Current Price₹ 1,195
Stock P/E73.9
Book Value₹ 78.2
ROCE28.2 %
ROE25.2 %
Dividend Yield0.13 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)24%
Compounded Profit Growth (TTM)20%
Consolidated figures.
Valuation
Market capRs 13,552 Cr
Enterprise valueRs 13,624 Cr
P/E (TTM)80.56x
Price to book60.69x
Price to sales21.95x
EV / EBITDA55.84x
EV / EBIT59.17x
EV / sales22.06x
Price to cash flow279.99x
Earnings yield1.24%
Profitability
Operating margin (excl. other income)21.05%
Operating margin (incl. other income)23.25%
EBITDA margin39.52%
Pre-tax margin36.15%
Net profit margin27.24%
Net margin, latest quarter27.54%
ROE32.24%
ROCE33.16%
ROA16.33%
ROE, 3-year average34.19%
ROCE, 3-year average34.91%
ROA, 3-year average17.92%
ROIC (approx.)56.37%
Tax rate27.52%
Other income / net worth4.23%
Growth
Sales growth (latest year)24.99%
Profit growth (latest year)24.22%
Sales CAGR, 3 years51.62%
Profit CAGR, 3 years51.17%
Sales growth QoQ5.94%
Profit growth QoQ3.74%
Sales growth YoY (latest quarter)49.16%
Profit growth YoY (latest quarter)65.31%
Per share
EPS (TTM)Rs 14.89
EPS (latest year)Rs 44.23
EPS (latest quarter)Rs 4.20
EPS, 3-year averageRs 212.29
Book value per shareRs 19.77
Sales per shareRs 54.67
Cash flow per shareRs 4.29
Free cash flow per shareRs -4.34
Efficiency
Asset turnover1.02x
Fixed asset turnover2.71x
Inventory turnover2.96x
Inventory days123 days
Debtor days80 days
Debtors turnover4.58x
Creditor days113 days
Cash conversion cycle372 days
Working capital days175 days
Leverage
Total debtRs 83 Cr
Cash and bankRs 10 Cr
Net debtRs 73 Cr
Debt to equity0.37x
Net debt / EBITDA0.30x
Interest coverage32.85x
Current ratio (filing 2026-03-31)3.09x
Quick ratio (filing 2026-03-31)2.02x
Trade payables (filing 2026-03-31)Rs 68 Cr
Owners' fund to total sources53.22%
Debt to assets19.80%
Cash flow
Cash from Operating Activity (latest year)Rs 48 Cr
Cash from Investing Activity (latest year)Rs -50 Cr
Cash from Financing Activity (latest year)Rs -10 Cr
Net Cash Flow (latest year)Rs -11 Cr
Free cash flow (latest year)Rs -49 Cr
FCFE (approx.: FCF + change in debt)Rs -50 Cr
Cash from ops / profit, 5 years0.41x
Sales to cash flow8.86x
Statement figures
Net sales (TTM)Rs 617 Cr
Net sales (latest year)Rs 429 Cr
Sales (latest quarter)Rs 172 Cr
Operating profit excl. other income (latest year)Rs 90 Cr
Operating profit (latest quarter)Rs 60 Cr
Other income (TTM)Rs 26 Cr
EBITDA (TTM)Rs 244 Cr
PBDT (TTM)Rs 237 Cr
Profit before tax (TTM)Rs 223 Cr
Tax (latest year)Rs 24 Cr
Net profit (TTM)Rs 168 Cr
Net profit (latest year)Rs 62 Cr
Net profit (latest quarter)Rs 47 Cr
Depreciation (TTM)Rs 14 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 210 Cr
Total expenditure (latest year)Rs 338 Cr
Total income (latest year)Rs 438 Cr
Share capitalRs 1 Cr
ReservesRs 222 Cr
Shareholders' fundsRs 223 Cr
Total assetsRs 420 Cr
Net blockRs 158 Cr
Capital work in progressRs 26 Cr
InvestmentsRs 3 Cr
ReceivablesRs 94 Cr
InventoryRs 71 Cr
Other liabilitiesRs 113 Cr
Shares outstanding (crore)11.29
Ownership
Promoter holding76.16%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SUDEEPPHRM | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +4.9% | -2.8% | +7.7 pts |
| 1 month | -2.5% | -6.8% | +4.3 pts |
| 3 months | +38.2% | -7.6% | +45.8 pts |
| 6 months | +102.5% | +0.4% | +102.1 pts |
35 mutual fund schemes hold about ₹1,006 Cr.
Over three months 8 bought more and 13 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Axis Small Cap Fund | 0.77% | 242 | -4% |
| SBI Healthcare Opp Fund | 2.84% | 165 | -11% |
| HDFC Manufacturing Fund | 0.93% | 99 | -5% |
| SBI MNC Fund | 1.24% | 83 | +100% |
| SBI Comma Fund | 6.73% | 83 | +100% |
| SBI Retirement Benefit Fund-Aggressive Plan | 1.63% | 53 | +100% |
| Edelweiss Recently Listed IPO Fund | 3.19% | 39 | +34% |
| Aditya Birla SL Small Cap Fund | 0.59% | 37 | -5% |
| PGIM India Small Cap Fund | 1.62% | 29 | -5% |
| SBI Retirement Benefit Fund-Aggressive Hybrid Plan | 1.36% | 23 | +100% |
| UTI Healthcare Fund | 1.43% | 21 | -40% |
| WOC Flexi Cap Fund | 0.22% | 20 | -8% |
| TRUSTMF Small Cap Fund | 0.64% | 18 | +100% |
| Quant Small Cap Fund | 0.05% | 18 | -5% |
| HDFC Innovation Fund | 0.45% | 14 | -10% |
| Edelweiss Equity Savings Fund(M | 0.49% | 8 | -10% |
| WOC Multi Cap Fund | 0.20% | 8 | -10% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.32% | 8 | -4% |
| Edelweiss Equity Savings Fund(M | 0.49% | 8 | -10% |
| WOC Multi Asset Allocation Fund | 0.08% | 7 | -8% |
| PGIM India ELSS Tax Saver Fund | 0.88% | 6 | +2% |
| Axis Equity Savings Fund | 0.54% | 5 | +2% |
| WOC Pharma and Healthcare Fund | 0.47% | 4 | -33% |
| WOC Balanced Advantage Fund | 0.15% | 3 | -2% |
| SBI Retirement Benefit Fund-Conservative Hybrid Plan | 0.67% | 2 | +100% |
Red flags
F-score 7 of 8| look | Inventory outrunning sales Inventory grew 94% vs sales +25% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹158 Cr +26.4% vs Jun 2025.
Net profit ₹41 Cr +32.3%.
Against our estimate for Jun 2026: sales -4.0%, profit -9.2% in line. Our estimate for Sep 2026: sales Rs 197 Cr, profit Rs 54 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-07-23 | Dividend - Rs 1.50 Per Share |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 monthsHigh low price variation greater than 75perc in previous 3 monthsScrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Sudeep Pharma Ltd?
Sudeep Pharma Ltd (SUDEEPPHRM) has a market capitalisation of Rs 13,500 Cr. at the 2026-10-01 close.
What is the P/E ratio of Sudeep Pharma Ltd?
Sudeep Pharma Ltd trades at a P/E of 73.9 on trailing twelve-month profit, at the 2026-10-01 close.
What were Sudeep Pharma Ltd's latest quarterly results?
In the Jun 2026 quarter, Sudeep Pharma Ltd sales was Rs 158 Cr (+26.4% vs Jun 2025) and net profit was Rs 41 Cr.
What is the 52-week high and low of Sudeep Pharma Ltd?
The 52-week high is Rs 1,378.00 and the 52-week low is Rs 524.05.